ASP5878 (3 mg/kg, orally, once daily) shows antitumor activity in a Hep3B2.1-7 subcutaneous xenograft and HCC orthotopic xenograft mouse model[1].
ASP5878 induces shrinkage of FGF19-expressing HCC xenograft model[1].
| Animal Model: | Four-week-old male nude mice (CAnN.Cg-Foxn1nu/CrlCrlj [nu/nu]) (Hep3B2.1-7 cells inoculated subcutaneously)[1]. |
| Dosage: | 3 mg/kg. |
| Administration: | Orally once daily from days 14 to 52. |
| Result: | Induced tumor regression by 9% and 88% at 1 and 3 mg/kg, respectively, without affecting the body weight for 14 days.
Induced the suppression of FGFR4 phosphorylation, mobility shift of FRS2, and suppression of ERK phosphorylation. |
| Animal Model: | HCC orthotopic xenograft model (mouse)[1]. |
| Dosage: | 3 mg/kg. |
| Administration: | Orally once daily for 24 days. |
| Result: | Exhibited a lower tumor burden than vehicle- and sorafenibtreated mice.
Induced sustained tumor regression without tumor regrowth.
|
